Esmolol CAS 81147-92-4

Esmolol, sold under the brand brevibloc, is a heart selective β 1 receptor blocker, with rapid onset and very short action time, has no significant intrinsic sympathomimetic or membrane stabilizing activity at the therapeutic dose. It is a class II antiarrhythmic drug. Esmolol blocks the sympathetic nervous system found in the heart and other organs of the body β- Adrenergic receptors reduce the strength and speed of heart contractions. Esmolol prevents the effects of two natural substances: epinephrine and norepinephrine.

Esmolol, also known as Ailuo, Emolol, Brevibloc, chemical name is 4{[3-[(1-methylethyl)amino]-2hydroxy]propoxy}phenylpropionic acid Methyl Methyl Hydrochloride, code-named ASL-8052, was created by American CriticalCare Company in 1982 and was first marketed in the United States in 1987. It is an ultra-short-acting cardioselective β1-receptor blocker. Intrinsic sympathomimetic activity and membrane stabilizing effect, high doses also have inhibitory effect on β2 receptors of tracheal and vascular smooth muscle, characterized by rapid onset of action and short duration of action. Clinically, it is mainly used for supraventricular tachycardia that occurs during anesthesia; it can also be used for myocardial infarction or after myocardial infarction, as well as for supraventricular tachyarrhythmia complicated by acute unstable angina pectoris, and can also be used in the perioperative period , Rapid antihypertensive treatment of hypertension during anesthesia.

Esmolol, as a second-generation B-adrenergic receptor blocker, was first approved for production and use by the US FDA in December 1986. blocker. It is rapidly distributed and eliminated in the body. Because it can prevent and treat almost all cardiovascular reactions caused by perioperative stimulation. Therefore, it is considered to be a “panacea” drug, and this pharmacological property makes it an ideal drug for preventing cardiovascular reactions caused by strong stimuli such as tracheal intubation under general anesthesia. It is now widely used in the control of intraoperative supraventricular tachyarrhythmia, tachycardia and hypertension, myocardial protection and electroconvulsive therapy. However, a large number of studies have shown that esmolol can not only inhibit the stress response to noxious stimuli during the perioperative period, but also has a certain analgesic effect, and has a synergistic effect with a variety of analgesic and sedative drugs, shortening the recovery time of patients. time. Reduce postoperative pain and complications such as nausea and vomiting.